Eng slo
EUR USD

 

The article was published by AICA, America Israel Cannabis Association.

Parents of children with severe epilepsy have reported incredible recoveries when their children were given cannabidiol, a derivative of marijuana. The drug, a non-psychoactive compound that occurs naturally in cannabis, has been marketed with epithets like Charlotte’s Web and Haleigh’s Hope.

But those parents were taking a risk; there has been no clinical data on cannabidiol’s safety of efficacy as an anti-epileptic. This week, doctors are presenting the first studies trying to figure out if cannabidiol actually works. They say the studies’ results are promising, but with a grain of salt.

The largest study being presented at the American Epilepsy Society meeting in Philadelphia this week was started in 2014 with 313 children from 16 different epilepsy centers around the country. Over the course of the three-month trial, 16 percent of the participants withdrew because the cannabidiol was either ineffective or had adverse side-effects, says Dr. Orrin Devinsky, a neurologist at the New York University Langone Medical Center and lead author on the study.

But for the 261 patients that continued taking cannabidiol, the number of convulsive seizures, called grand mal or tonic-clonic seizures, went down by about half on average. Devinsky says that some children continued to experience benefits on cannabidiol after the trial ended. “In the subsequent periods, which are very encouraging, 9 percent of all patients and 13 percent of those with Dravet Syndrome epilepsy were seizure-free. Many have never been seizure-free before,” he says. It’s one of several papers on cannabidiol being presented this week at the American Epilepsy Society meeting in Philadelphia.

Twenty-five of those patients were followed for a yearlong study also presented at the meeting. Some of those patients did better, but one ended up doing worse. “A drug can induce an increase in seizures,” says Dr. Maria Roberta Cilio, a pediatric neurologist at UCSF Benioff Children’s Hospital who led that study. This happened with one of her patients. “For one particular child, the more the dose of [cannabidiol] was increasing, that increase was paralleled with an increase in seizure frequency,” she says.

Some patients in Devinsky’s trial also did worse while on cannabidiol, but he thinks there’s no way to tell if it was because of the drug or something else. He says we won’t know until a full clinical trial has run its course. Without that, the perceived effects of the drug might be a placebo effect or it could be some other confounding factor that hasn’t been caught in the study. What’s more, a few hundred patients isn’t a lot of patients, and doctors still need to see what will happen when a patient is on cannabidiol for more than a few months.

Epilepsy can be one of the most difficult syndromes to treat. About a third of patients have an intractable form of epilepsy. It’s common for children and adults with treatment-resistant epilepsy to exhaust the list of anti-seizure medications to little or no effect.

Jaren Hansen is a 7-year-old boy with Lennox-Gastaut Syndrome, a form of treatment-resistant epilepsy. When he was 2, he started having seizures. His doctors diagnosed him with epilepsy and started him on one anti-seizure medication. Then they added another, and then another.

None of them seemed to be working. “He tail spun again and had a tonic-clonic seizure every day. At that point, he was on three seizure medications, and we weren’t seeing any control. Things were just tumbling downward,” says his mother, Nicole Hansen from Necedah, Wisc. “At one point, blood levels of Depakote [an anti-epileptic medication] were toxically high. We needed to try something else. We were scared for his long-term health based on just the side effects of the medicine.”

Hansen, who works as a cranberry grower in Wisconsin, started researching her son’s illness. She found an online chat group with other parents who were discussing medical cannabis, and decided to try one of the commercially available cannabidiol products. But it was difficult. States like Wisconsin do allow the shipment of cannabidiol supplements and oils that don’t contain tetrahydrocannabinol or THC, the psychoactive compound in marijuana, but most doctors won’t touch it. “They won’t even prescribe it because there are too many loopholes and too much work,” Hansen says.

Lack of physician input often leaves parents on their own, Hansen says. That presents more challenges. “You have to make sure the company can replicate the same product over and over. A small change in the ratio of THC to cannabidiol can cause the child’s seizures to increase or come back. You have to make sure there are no microbial issues like molds or funguses or pesticides.”

That people are treating themselves or their children with cannabis products is troubling to physicians. “It’s a very worrisome time. People go off and do their own thing, if things go wrong, you don’t know why. You want data, and you don’t have it, and all the families are just trying things,” says Dr. Brenda Porter, a pediatric neurologist at Stanford University School of Medicine who was not involved in the study.

Devinsky says parents either have to purchase the cannabidiol from an artisanal distributor of hemp products or compound the drug themselves. Either way, “the consistency from batch to batch is quite uncertain,” he says.

And people sometimes try different formulations from several companies in the hope one will work. “As a practitioner, I have had families move to Colorado, and many tried multiple different products,” Devinsky says. That makes it really difficult to tell what is or isn’t working. “As a doctor, I often don’t feel like I know which of many factors is contributing to a patient doing better or worse. We absolutely need rigorous, scientific data on this,” he says.

Even though the results presented at the American Epilepsy Society meeting look encouraging, researchers caution that there’s no promise cannabidiol is really going to work for many of these treatment resistant epilepsy syndromes. Until there is a full clinical trial done with a placebo-controlled element, Devinsky and others say it’s impossible to tell if cannabidiol is having a real effect on epilepsy. That takes time and puts parents in a difficult position, he says. “Parents are desperate and they feel the medical community has failed them, which is true in many cases.”

Hansen agrees with Devinsky; she feels that the clinical trials need to be finished as fast as possible. “There are parents out there doing whatever they can and experimenting with cannabis. We need the medical professionals so they can help make the proper recommendations,” she says. “But I can’t blame them for trying. When you are seeing your child dying, and knowing that you could do something to help them, how can you not do something as a parent?”

After Hansen put her son on cannabidiol he continued to have seizures, but the number of convulsive seizures went down. Then he caught a stomach flu, and things spiraled out of control. The tonic-clonic seizures came back, violently, and he nearly died. “They put him into am medically induced coma in hopes that it would reset his brain.” she says. “By God’s grace, truly, and by a miracle it did.”

Jaren is not on cannabidiol anymore. He’s on three different medications now, including a benzodiazepine and a barbiturate. “Both in the long-term can cause brain atrophy,” Hansen says. “At some point, we have to start weaning him off, and nothing else has worked. And he needs more than just cannabidiol.” She’s hopeful that cannabis research will bring the science to a point where doctors can begin looking into mixtures of cannabidiol and THC together.

Full on, randomized clinical trials testing cannabidiol for epilepsy are already underway, but it will still be some time until the results are out. Until then, Devinsky says, “Wait.”

© Patron. Online store by Shopamine. Cookie Settings My Data

In addition to mandatory cookies, we also use analytical and advertising cookies, as well as social network cookies on the Patron website.

If you agree with this, please click on the I ACCEPT button. For a detailed description and in order to set the use of individual cookies, click on the COOKIE SETTINGS link.

×
Managing cookies on the Patron website
Mandatory cookies

are cookies that are essential for the proper functioning of the website, whereby the transmission of information in the communication network would not be possible without them. These cookies are also necessary in order for us to offer you the services, which are available on our website. They allow you to log in to the user profile, select the language, agree to the terms and conditions and identify the session of the user. We are not obliged to obtain consent for their use.

Analytical cookies

These cookies help us understand how our visitors use our website. They help us improve the user experience and identify user requirements and trends. We only use these cookies if you have explicitly consented to their use.

Advertising cookies

Third-party plug-ins and tools used as cookies enable various functionalities to work, help us analyse the frequency of visits and how the website is used. If an individual does not agree to the use of these cookies, they will not be installed, while it may however happen, that some interesting features of the website will not be available. We only use these cookies if you have explicitly consented to their use.

Social network cookies

These cookies make it possible for us to provide content for posts on social media and record your actions so that we may provide a more personal and enhanced user experience. We use these cookies only if you are logged into a Twitter, Facebook or Google user account when using the website.

1. General information about cookies 1.1. What are cookies?

Cookies are small text files that most modern websites store on the devices of their visitors, i.e. people who access certain websites on the Internet with their devices. The storing of cookies is under the complete control of the user, since users can easily configure their browser to restrict or disable the storage of cookies.

While visiting the website and its subpages and performing operations on the website, your computer, phone or tablet, automatically or after gaining your explicit consent, stores certain cookies through which various data can be recorded.

1.2. How do they work and why we use them?

Each visitor or shopper is assigned a cookie in order to identify him and ensure traceability at the beginning of each use of the online store. The servers provided to the company by the subcontractor automatically collect data on how visitors, shop owners or shoppers use the online store and store this data in the form of an activity log.

The servers store information about the use of the online store, statistics and IP numbers. Data on the use of the online store by shoppers can be used by the company for compiling anonymous statistics that help us improve the user experience as well as market products and / or services through an online store.

Indirectly and upon obtaining consent, the online store may also store external service cookies on the visitor's or shopper's device (e.g. Google Analytics) which are used to collect data on website visits. Regarding external services, the rules and general conditions on the processing of personal data, which are available at the links below, apply.

2. Permission to use cookies

If the settings of the browser with which you visit the website are such, that they accept all cookies, it means that you agree to their use. In case you do not want to use cookies on this website or you want to remove them, you may follow the procedure below. Removing or blocking cookies may result in suboptimal performance of this website.

3. Mandatory and optional cookies and your consent 3.1. We are not required to gain your consent for the use of mandatory cookies:

Mandatory cookies are cookies, that are essential for the proper functioning of the website, whereby the transmission of information in the communication network would not be possible without them. These cookies are also necessary in order for us to offer you the services, which are available on our website. They enable login into the user profile, language selection, agreeing to the terms and conditions and user session identification.

3.2. Cookies that are not necessary for the normal operation of the website, and for which we are obliged to obtain your consent (optional cookies):

Analytical cookies

These cookies help us understand how our visitors use our website. They help us improve the user experience and identify user requirements and trends. We only use these cookies if you have explicitly consented to their use.

Advertising cookies

Third-party plug-ins and tools used as cookies enable various functionalities to work, help us analyse the frequency of visits and how the website is used. If an individual does not agree to the use of these cookies, they will not be installed, while it may however happen, that some interesting features of the website will not be available. We only use these cookies if you have explicitly consented to their use.

Social network cookies

These cookies make it possible for us to provide content for posts on social media and record your actions so that we may provide a more personal and enhanced user experience. We use these cookies only if you are logged into a Twitter, Facebook or Google user account when using the website.

4. How to manage cookies?

You can manage cookies by clicking on the "Cookie settings" link in the footer of the website.

You can also control and change cookie settings in your own web browser.

In case you want to delete cookies from your device, we advise you to follow the described procedures, by doing so, you will most likely limit the functionality of not only our website but also most other websites, as the majority of modern websites use cookies.